Does Rallies show 13F holders for ADCT?

Yes. Rallies tracks hedge fund and 13F ownership data for ADCT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ADCT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ADCT. It does not provide personalized investment advice.

ADCT (ADC Therapeutics SA) Stock Analysis - Hedge Fund Holdings

ADC Therapeutics SA (ADCT) is a publicly traded Healthcare sector company. As of May 21, 2026, ADCT trades at $3.14 with a market cap of $403.20M and a P/E ratio of -3.25. ADCT moved +3.18% today. Year to date, ADCT is -8.99%; over the trailing twelve months it is +50.70%. Its 52-week range spans $1.05 to $4.98. Analyst consensus is strong buy with an average price target of $8.00. Rallies surfaces ADCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ADCT stock?

Hedge funds tracked by Rallies that own ADCT include Redmile Group, Orbimed Advisors, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for ADC Therapeutics SA.

ADCT Key Metrics

Key financial metrics for ADCT
Metric	Value
Price	$3.14
Market Cap	$403.20M
P/E Ratio	-3.25
EPS	$-0.99
Dividend Yield	0.00%
52-Week High	$4.98
52-Week Low	$1.05
Volume	592.16K
Avg Volume	0
Revenue (TTM)	$79.17M
Net Income	$-136.99M
Gross Margin	0.00%

Top Hedge Funds Holding ADCT

Redmile Group holds 15.47M shares of ADCT, changed -1.25% as of Mar 31, 2026.
Orbimed Advisors holds 1.32M shares of ADCT, changed -77.36% as of Mar 31, 2026.
Panagora Asset holds 691.27K shares of ADCT, changed +16.33% as of Mar 31, 2026.

Latest ADCT News

ADC Therapeutics Q1 Revenue $20.03M Beats Estimates, EPS -$0.21 Misses — May 4, 2026
ADC Therapeutics Cuts 2026 Revenue Forecast to $76.6M, Q1 Sales Seen at $19.2M — May 1, 2026
ADC Therapeutics Q4 Revenue Up 36%, Loss Narrows to $0.04 — Mar 10, 2026
ADC Therapeutics Forecasts Q4 Loss, Full-Year Revenue of $80.6M; Analysts See 88.6% Upside — Mar 9, 2026

Recent ADCT Insider Trades

Redmile Group, LLC sold 2.63M (~$8.64M) on Apr 2, 2026.
Redmile Group, LLC sold 2.53M (~$8.29M) on Apr 2, 2026.
Redmile Group, LLC sold 169.26K (~$643.04K) on Apr 1, 2026.

ADCT Analyst Consensus

3 analysts cover ADCT: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.00.

Common questions about ADCT

Who owns ADCT stock?: Hedge funds tracked by Rallies that own ADCT include Redmile Group, Orbimed Advisors, and Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for ADC Therapeutics SA.
Does Rallies show 13F holders for ADCT?: Yes. Rallies tracks hedge fund and 13F ownership data for ADCT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ADCT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ADCT. It does not provide personalized investment advice.